SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Advanced Enzyme Technologies Ltd

BSE: 540025 NSE: ADVENZYMES ISIN: INE837H01020
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Advanced Enzyme Technologies Ltd belong to?
Advanced Enzyme Technologies Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Advanced Enzyme Technologies Ltd a good quality company?
Advanced Enzyme Technologies Ltd is a good quality company, based on a consistently good 10 year financial track record.
Q.3 Is Advanced Enzyme Technologies Ltd undervalued or overvalued?
Advanced Enzyme Technologies Ltd appears Somewhat Undervalued, as its key valuation ratios are below with their past averages.
Q.4 Is Advanced Enzyme Technologies Ltd a good buy now?
Advanced Enzyme Technologies Ltd is a neutral opportunity now, based on stable price trend analysis suggesting prices may move sideways. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Advanced Enzyme Technologies Ltd?
Advanced Enzyme Technologies Ltd revenue growth is -3.9% for FY-2025 , which is below its 5 year CAGR of 7.3% , indicating slower growth.
Q.2 Gross Profit margin of Advanced Enzyme Technologies Ltd?
Advanced Enzyme Technologies Ltd Gross profit margin which is the profit after deduction of direct costs, is 37.5% for FY-2025 , which is above its 5 year median of 37.3% , indicating increasing margins.
Q.3 Operating Profit Margin of Advanced Enzyme Technologies Ltd?
Advanced Enzyme Technologies Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 20.19% for FY-2025 , which is below its 5 year median of 26.7% indicating decreasing margins.
Q.4 Net Profit Margin of Advanced Enzyme Technologies Ltd?
Advanced Enzyme Technologies Ltd Net Profit Margin is 29.15% for FY-2025 , is above with its 5 year median of 25.05%, indicating increasing margins.
Current Level Historic Median
Gross Profit Margin 37.5 37.3
Operating Profit Margin 20.19 26.7
Net Profit Margin 29.15 25.05
Q.5 Return on Asset of Advanced Enzyme Technologies Ltd?
Advanced Enzyme Technologies Ltd Return on Asset is 15.5%, which is in line with its 5 year historical median of 15.5%, indicating stable asset utilization efficiency.
Q.6 Return on Equity (ROE) of Advanced Enzyme Technologies Ltd?
Advanced Enzyme Technologies Ltd Return on equity is 17.04% for FY-2025 , which is in line with its historical median of 17.04%, indicating the business is making similar use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Advanced Enzyme Technologies Ltd?
Advanced Enzyme Technologies Ltd Return on capital employed is 20.01% for FY-2025 , which is above its estimated weighted average cost of capital(WACC) 14%, indicating value creation.
Q.8 Cash conversion cycle of Advanced Enzyme Technologies Ltd?
Advanced Enzyme Technologies Ltd Cash conversion cycle is 152 days, above its historical median of 126 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 0.53 0.57
ROE 17.04 17.04
ROCE 20.01 20.01
Cash Conversion Cycle 152 days 126 days
Q.9 Debt to Equity ratio of Advanced Enzyme Technologies Ltd?
Advanced Enzyme Technologies Ltd Debt-to-Equity ratio is 0.00 , which is lower with the industry average of 0.15 , indicating lower debt levels in the industry.
Q.10 Debt to cash flow from operations of Advanced Enzyme Technologies Ltd?
Advanced Enzyme Technologies Ltd Debt to cash flow from operations is 0 , which is at a healthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Advanced Enzyme Technologies Ltd?
Promoters hold 43.26% of the Advanced Enzyme Technologies Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Advanced Enzyme Technologies Ltd vs industry peers?
Advanced Enzyme Technologies Ltd revenue CAGR is 7.28% , compared to the industry median CAGR of 5.51% , indicating faster growth and gaining its market share.
Profit Metrics
Current Level Industry Median
Revenue 351.4 138.8
Gross Profit 131.6 16.2
Operating Profit 71 16
Net Profit 102 5.3
Operating Efficiency
Current Level Industry Median
Asset Turnover 0.53 0.79
ROE 17.04 9.17
ROCE 20.01 11.78
Cash Conversion Cycle (days) 151.55 76

Valuation & price assessment

Q.1 Stock return of Advanced Enzyme Technologies Ltd over the last decade?
Over the last 5 year(s), the stock has delivered a CAGR of -4.97% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price - -5% 5.1% 0.5%
Q.3 Valuation ratios of Advanced Enzyme Technologies Ltd vs historical?
The current P/E is lower that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 27.79 48.64 40.28
Price to Book 4.9 6.57 2.77
Price to Sales 7.91 11.31 2.65
EV to EBITDA 20.82 32.07 15.67

Check more companies

1. Ajanta Pharma
2. JB Chem & Pharma
3. Emcure Pharma
4. Gland Pharma
5. Wockhardt
6. Pfizer
7. Sai Life Sciences
8. Astrazeneca Pharma I
9. Piramal Pharma
10. Acutaas Chemicals
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×